SNO 27th Annual Meeting

Tampa, November 18 – 20, 2022

Visit us at Booth #500

ONC201 Phase 3 in H3 K27M Diffuse Glioma

Join us for a symposium discussing the development, recent findings, and future clinical evaluation of ONC201 in H3 K27M-mutant glioma in the ACTION Trial (NCT05580562)
A SNO 2022 Annual Meeting Independent Supported Session
Date and Time: Saturday, November 19, 2022 from 12:45 p.m. – 2:15 p.m. ET
Rooms 120 & 121 (1st floor)

Chimerix Sponsored

ONC108: A randomized phase 3 study of ONC201 in patients with newly diagnosed H3 K27M-mutant diffuse glioma
Abstract Number: RTID-01
Date and Time: November 18, 2022 from 7:30 p.m. – 9:30 p.m. ET
Presenter: Timothy F. Cloughesy, MD


Role of ClpP and mitochondrial metabolism in the anti-cancer effects of imipridone ONC201 and ONC206 in glioblastoma and DIPG
Abstract Number: EXTH-104
Date and Time: November 18, 2022 from 7:30 p.m. – 9:30 p.m. ET
Presenter: Varun V. Prabhu, Ph.D.

Other ONC201 Posters/Presentations

Preclinical and case study examination of the combination of the CLPP agonist ONC201 with the PI3K/AKT inhibitor paxalisib for the treatment of diffuse midline glioma
Abstract Number: EXTH-12
Date and Time: November 18, 2022 from 9:00 a.m. – 10:30 a.m. ET
Presenter: Matthew D. Dunn, Ph.D.


Antagonism of DRD2 using ONC201 increased expression of antigen presentation pathway proteins in diffuse midline glioma, recruiting tumor infiltrating lymphocytes in vivo
Abstract Number: TMIC-06
Date and Time: November 18, 2022 from 7:30 p.m. – 9:30 p.m. ET
Presenter: Mathew D. Dunn, Ph.D.


BH3 profiling identifies ONC201/TIC10 as a promising partner of ABT-263 in medulloblastoma in vitro
Abstract Number: EXTH-86
Date and Time: November 18, 2022 from 7:30 p.m. – 9:30 p.m. ET
Presenter: Varun Prabhu


Diffuse midline glioma-adaptive combinatory trial (DMG-ACT): A combination platform trial in pediatric and young adult patients with diffuse midline glioma
Abstract Number: CTNI-09
Date and Time: November 18, 2022 from 7:30 p.m. – 9:30 p.m. ET
Presenter: Andrea T. Franson, MD, MS


Integrated stress response activators synergistically induce apoptosis and suppress proliferation in diffuse intrinsic pontine glioma
Abstract Number: EXTH-75
Date and Time: November 18, 2022 from 7:30 p.m. – 9:30 p.m. ET
Presenter: Orlandi V. Novak

For more information about ONC201 and the ACTION Study